BioNTech live chart

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

Mga pinakabagong balita

Tommy Yap 2025 Mar 22, 16:00

Week Ahead: Investor Eyes on U.S. Inflation & Core PCE for Fed’s Next Move

Forex Indices
Frances Wang 2025 Mar 20, 16:00

Stock indices news: US stock indices rose on Fed decision

Indices
Tommy Yap 2025 Mar 20, 16:00

Morning Note: Oil Sanctions, Canada Data, Ripple's Space Gamble

Morning Note Oil Forex
Frances Wang 2025 Mar 19, 16:00

US stock indices update: NASDAQ 100, Dow Jones 30 and S&P 500 Forecast

Indices
Tommy Yap 2025 Mar 19, 16:00

Morning Note: SNB Rate Cut Expected, BoE Decision & Accenture Earnings in Focus

Morning Note Forex
Frances Wang 2025 Mar 18, 16:00

Stock market today: NASDAQ Index, SP500, Dow Jones Forecasts

Stocks
Tommy Yap 2025 Mar 18, 16:00

Morning Note: BoJ Holds Rates, Fed Decision Looms & Tencent Earnings in Focus

Morning Note BoJ Fed
Frances Wang 2025 Mar 17, 16:00

Stock market today: Dow, S&P 500, Nasdaq remain steady on tariff tension

Stocks Indices

Info

Spread

1.0234

Spread (%)

1.0765 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

22888433664

Natitirang Pagbabahagi

239971008

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

2022-06-17

Araw ng Pag-alis ng Karapatan sa Dividend

2022-06-02

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-3.02

Alamin ang Higit Pa Tungkol sa Instrumentong ito

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Mga kaugnay na instrumento

view_all_instruments
Trustpilot